Adaptimmune Snags FDA Nod For TCR Therapy Tecelra

The approval marks the first for an engineered cell therapy for a solid tumor indication, and the company has jumped on commercialization efforts.

Adaptimmune received accelerated approval from the FDA for its TCR therapy, Tecelra • Source: Shutterstock

More from New Products

More from Scrip